INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study

MELBOURNE, Australia, April 14, 2019 /PRNewswire/ — The Janssen
Pharmaceutical Companies of Johnson & Johnson announced today
new results from the Phase 3 CREDENCE study, showing that
INVOKANA® (canagliflozin) demonstrated a 30 percent reduction in
the risk of the primary composite…

Source: FS – Machinery
INVOKANA® (canagliflozin) Significantly Reduces the Risk of Renal Failure in Patients with Type 2 Diabetes and Chronic Kidney Disease in the Landmark Phase 3 CREDENCE Study



Leave a Reply